Humacyte Q2 net income $36.9M driven by non-cash gains; HAVs show promise in Ukraine

Humacyte, Inc.

2022-Q2 EPS reported $0.16

Cash $189.0M as of June 30, 2022; company expects runway through 2024, past potential HAV approval in vascular trauma.
Net income $36.9M vs net loss $17.2M in Q2 2021; driven by $55.4M non-cash gain from contingent earnout remeasurement.
Revenue $1.3M (grants), up from $0.7M; R&D expense $14.7M, G&A $5.2M.
HAVs implanted in Ukraine under humanitarian initiative reportedly functioning and infection-free, saving limbs.
Appointed Diane Seimetz to Board and Shamik Parikh as CMO; preclinical small-diameter HAV data in CABG presented.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.